Recordati SpA – Strategy, SWOT and Corporate Finance Report

Recordati SpA – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, dermatology, central nervous system disorders, musculo-skeletal disorders and analgesia and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over the counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It also produces pharmaceutical chemicals, such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries where it is present and through licensees in other places. Recordati is headquartered in Milan, Italy.

Scope

Detailed information on Recordati SpA required for business and competitor intelligence needs

A study of the major internal and external factors affecting Recordati SpA in the form of a SWOT analysis

An in-depth view of the business model of Recordati SpA including a breakdown and examination of key business segments

News about Recordati SpA, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Recordati SpA and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Recordati SpA as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Recordati SpAs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Enervit SpA

SOL SpA

MolMed SpA

Chiesi Farmaceutici SpA

Zambon Company SpA

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Recordati SpA - Key Facts

Recordati SpA - Key Employees

Recordati SpA - Key Employee Biographies

Recordati SpA - Major Products and Services

Recordati SpA - History

Recordati SpA - Company Statement

Recordati SpA - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Recordati SpA - Business Description

Business Segment: Pharmaceutical Segment

Performance

Business Segment: Rare Diseases

Overview

Performance

Business Segment: Specialty and Primary Care

Overview

Geographical Segment: Africa

Performance

Geographical Segment: America

Performance

Geographical Segment: Australasia

Performance

Geographical Segment: Europe

Performance

R&D Overview

Recordati SpA - SWOT Analysis

SWOT Analysis - Overview

Recordati SpA - Strengths

Recordati SpA - Weaknesses

Recordati SpA - Opportunities

Recordati SpA - Threats

Recordati SpA - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Recordati SpA, Recent Deals Summary

Section 5 Company’s Recent Developments

May 08, 2019: Recordati announces growth in the first quarter 2019

Feb 28, 2019: Recordati: Sales € 1,352.2 million (+5.0%), EBITDA € 499.1 million (+9.8%), operating income € 442.2 million (+8.8%) and net income € 312.4 million (+8.2%). 2018 dividend € 0.92 (+8.2%)

Feb 11, 2019: Recordati: Preliminary 2018 results confirm continued growth of sales and profitability

Dec 06, 2018: Recordati: Resignation of Board Members; co-option of three new Directors; appointment of chairman; an ordinary general meeting of the shareholders is convened to appoint a new Board of Directors

Oct 30, 2018: Recordati announces sales and margin growth in the first nine months 2018. revenues +5.1%, ebitda +11.1%, operating income +9.6%,  net income +8.2%. interim dividend € 0.45 (+7.1%).

Jul 26, 2018: Recordati announces sales and margin growth in the first half

2018. Revenues +6.9%, operating income +14.1%, net income +11.7%

Jul 02, 2018: CVC to buy majority stake in drugmaker Recordati for €3bn

May 08, 2018: Recordati Announces Sales and Margin Growth in the First Quarter 2018

Apr 30, 2018: Recordati Selects IQVIA’s OCE Technology Platform and OneKey Information Services

Mar 15, 2018: Recordati: Board Approves The 201 7 Accounts

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Recordati SpA, Key Facts

Recordati SpA, Key Employees

Recordati SpA, Key Employee Biographies

Recordati SpA, Major Products and Services

Recordati SpA, History

Recordati SpA, Subsidiaries

Recordati SpA, Key Competitors

Recordati SpA, Ratios based on current share price

Recordati SpA, Annual Ratios

Recordati SpA, Annual Ratios (Cont…1)

Recordati SpA, Annual Ratios (Cont…2)

Recordati SpA, Interim Ratios

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Recordati SpA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Recordati SpA, Performance Chart (2014 – 2018)

Recordati SpA, Ratio Charts

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports